Year 2019, Volume 5, Issue 4, Pages 707 - 711 2019-07-04

Statin-associated myopathy: a general overview

Allam Harfoush [1]

33 173

Among the amazing turn of events in preventing and reducing the risk of cardiovascular diseases since the discovery of statins, thousand of physicians started to prescribe it as a regular life-long treatment, but regarding the expanding number of patients on statin therapy, a wide spectrum of side effects started to appear. Statin-associated myopathy considered as one of the most common side effects and could be subtle for a long time, we performed a review to provide a clinical summary of statin-associated myopathy and to discuss possible mechanisms of risk factors and management of statin-associated myopathy. 

Statin-associated myopathy, myalgia, myositis, rhabdomyolysis
  • [1] Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-360.
  • [2] Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
  • [3] Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, at al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22.
  • [4] Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.
  • [5] Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
  • [6] Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008;337:a2286.
  • [7] Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S58-71.
  • [8] Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403.
  • [9] Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10:373-87.
  • [10] Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep 2011;63:859-66.
  • [11] Best tests: Investigating myalgia in patients taking statins, The Best Practice Advocacy Centre New Zealand (bpacnz). August 2014.
  • [12] de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ; Dutch ExPRESS Investigator Group. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002;90:181-4.
  • [13] Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
  • [14] Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.
  • [15] Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
  • [16] Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
  • [17] Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68.
  • [18] Jacobson TA. NLA Task Force on Statin Safety--2014 update. J Clin Lipidol 2014;8(3 Suppl):S1-4.
  • [19] Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014;63 Suppl 3:S327-34.
  • [20] Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012;40:188-94.
  • [21] Schuster B. Monitorıng of creatine kinase (CK) in patients on statin therapy. The Rx Files: Q&A Summary, March 2002.
  • [22] Husband A. Managing statin-induced myopathy. Clin Pharmacist 2009;1:319-20.
Primary Language en
Journal Section Reviews

Orcid: 0000-0001-7317-4237
Author: Allam Harfoush (Primary Author)
Institution: Department of Cardiovascular Diseases, Tishreen Hospital, Lattakia, Syria
Country: Syria


Publication Date: July 4, 2019

EndNote %0 The European Research Journal Statin-associated myopathy: a general overview %A Allam Harfoush %T Statin-associated myopathy: a general overview %D 2019 %J The European Research Journal %P -2149-3189 %V 5 %N 4 %R doi: 10.18621/eurj.416772 %U 10.18621/eurj.416772